Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Journal Article (Journal Article)


To describe predominantly persistent subretinal fluid (SRF) in eyes receiving ranibizumab or bevacizumab for neovascular age-related macular degeneration and to compare visual acuity (VA) to eyes with nonpersistent SRF.


Cohort within randomized clinical trial.


Comparison of Age-related Macular Degeneration Treatments Trials patients assigned to pro re nata treatment.


Graders evaluated monthly OCT scans for SRF. Predominantly persistent SRF through week 12 was defined as SRF at baseline and weeks 4, 8, and 12. Predominantly persistent SRF through 1 or 2 years was defined as SRF in 80% or more of visits by years 1 or 2, respectively. Linear regression models including baseline predictors of VA and predominantly persistent intraretinal fluid (IRF) were used to evaluate mean differences in vision outcomes.

Primary outcome measures

Predominantly persistent SRF through year 1, adjusted VA score and VA change, and foveal SRF thickness.


Among 406 eyes with baseline SRF, SRF persisted in 108 eyes (26.6%) through week 12, in 94 eyes (23.2%) through year 1, and in 77 eyes (19.0%) through year 2. Adjusted VA means at year 1 were similar between eyes with predominantly persistent versus non persistent SRF by week 12 (68.1 vs. 70.2 letters; P = 0.18), year 1 (67.6 vs. 70.2 letters; P = 0.11), and year 2 (71.4 vs. 70.9 letters; P = 0.78). Adjusted changes in mean VA at year 1 were similar between eyes with predominantly persistent versus nonpersistent SRF by week 12 (6.3 vs. 7.6 letters; P = 0.38), year 1 (5.5 vs. 7.8 letters; P = 0.14), and year 2 (8.1 vs. 7.7 letters; P = 0.78). Among eyes with predominantly persistent SRF through year 1, foveal SRF was absent in 46 eyes (48.9%), thickness was 1 to 200 μm in 48 eyes (50.0%) and more than 200 μm in 1 eye (1.1%) at year 1.


Eyes with predominantly persistent and nonpersistent SRF through week 12, year 1, or year 2 showed similar VA outcomes after adjustment for baseline covariates and persistent IRF. At the foveal center, predominantly persistent SRF was most commonly absent or present in small quantities.

Full Text

Duke Authors

Cited Authors

  • Core, JQ; Pistilli, M; Daniel, E; Grunwald, JE; Toth, CA; Jaffe, GJ; Hua, P; Martin, DF; Ying, G-S; Maguire, MG; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group,

Published Date

  • October 2021

Published In

Volume / Issue

  • 5 / 10

Start / End Page

  • 962 - 974

PubMed ID

  • 34126249

Pubmed Central ID

  • PMC8478884

Electronic International Standard Serial Number (EISSN)

  • 2468-6530

International Standard Serial Number (ISSN)

  • 2468-7219

Digital Object Identifier (DOI)

  • 10.1016/j.oret.2021.06.003


  • eng